Impact of performance status on efficacy of systemic therapy for prostate cancer: a meta-analysis. | 2023 | BJU International |
Systemic therapies for high-volume metastatic hormone-sensitive prostate cancer: a network meta-analysis. | 2023 | Acta Oncologica |
Based on ARASENS trial: efficacy and safety of darolutamide as an emerging option of endocrinotherapy for metastatic hormone-sensitive prostate cancer—an updated systematic review and network meta-analysis. | 2023 | Journal of Cancer Research and Clinical Oncology |
Efficacy of systemic treatment in prostate cancer patients with visceral metastasis: a systematic review, meta-analysis, and network meta-analysis. | 2023 | The Journal of Urology |
Triplet or doublet therapy in metastatic hormone-sensitive prostate cancer: updated network meta-analysis stratified by disease volume. | 2023 | European Urology Focus |
First-line systemic treatment options for metastatic castration-sensitive prostate cancer: a living systematic review and network meta-analysis. | 2023 | JAMA Oncology |
Comparative efficacy of second-generation androgen receptor inhibitors for treating prostate cancer: a systematic review and network meta-analysis. | 2023 | Frontiers in Endocrinology |
Comparison of doublet and triplet therapies for metastatic hormone-sensitive prostate cancer: a systematic review and network meta-analysis. | 2023 | Frontiers in Oncology |
The efficacy and adverse events of conventional and second-generation androgen receptor inhibitors for castration-resistant prostate cancer: a network meta-analysis. | 2023 | Frontiers in Endocrinology |
Risk of cognitive impairment in men with advanced prostate cancer treated with NHAs: a systematic review and network meta-analysis. | 2023 | Clinical and Translational Science |
Comparison of treatments for nonmetastatic castration-resistant prostate cancer: matching-adjusted indirect comparison and network meta-analysis. | 2022 | Journal of the National Cancer Institute |
Efficacy and safety of therapies for advanced prostate cancer in Asia: evidence from a systematic literature review. | 2022 | Therapeutic Advances in Medical Oncology |
Androgen receptor signaling inhibitors in addition to docetaxel with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis. | 2022 | European Urology |
Treatments for metastatic hormone-sensitive prostate cancer: systematic review, network meta-analysis, and benefit-harm assessment. | 2022 | European Urology Oncology |
Systemic triplet therapy for metastatic hormone-sensitive prostate cancer: A systematic review and network meta-analysis. | 2022 | Frontiers in Pharmacology |
Addition of androgen receptor-targeted agents to androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis. | 2022 | ESMO Open |
Impact of new systemic therapies in overall survival in non-metastatic castration resistant prostate cancer: systematic review and meta-analysis. | 2022 | Clinical Genitourinary Cancer |
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. | 2021 | Prostate Cancer and Prostatic Diseases |
Novel androgen receptor inhibitors in non-metastatic, castration-resistant prostate cancer: a systematic review and network meta-analysis. | 2021 | Frontiers in Oncology |
Androgen receptor axis-targeted agents for non-metastatic castration-resistant prostate cancer impact on overall survival and safety profile: an updated systematic review and meta-analysis. | 2021 | Minerva Urology and Nephrology |
Systemic management for nonmetastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. | 2020 | American Journal of Clinical Oncology |
A systematic review and network meta-analysis of novel androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer. | 2020 | Clinical Genitourinary Cancer |
Role of novel hormonal therapies in the management of non-metastatic castration-resistant prostate cancer: a literature-based meta-analysis of randomized trials. | 2020 | Clinical and Translational Oncology |
Apalutamide, enzalutamide, and darolutamide for non‑metastatic castration‑resistant prostate cancer: a systematic review and network meta‑analysis. | 2020 | International Journal of Clinical Oncology |
Evaluation of cognitive function in trials testing new-generation hormonal therapy in patients with prostate cancer: a systematic review. | 2020 | Cancers |
New hormonal agents in patients with nonmetastatic castration-resistant prostate cancer: meta-analysis of efficacy and safety outcomes. | 2019 | Clinical Genitourinary Cancer |